RPRX - NASDAQ
Royalty Pharma plc
$54.97
+1.8%Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
At a Glance
Live SnapshotRoyalty Pharma plc Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
Royalty Pharma plc Cash Flow Statement
RPRX • NASDAQ
| Royalty Pharma plc Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
1.3B | 1.3B | 1.7B | 230.1M | 1.2B | 1.7B | 2.5B | 1.5B | 1.3B | |
3.9M | 0.0 | 0.0 | 5.7M | 23M | 23.1M | 23.9M | 33.3M | 33.3M | |
289.9M | 2.3M | 2.4M | 2.2M | 2.4M | 5.4M | 0.0 | 0.0 | 0.0 | |
889M | 1.4B | 1.3B | 1.9B | 767.2M | 228.2M | -793.4M | 1.6B | 1.5B | |
-17.2M | 53.4M | 5.4M | 32.7M | -16.3M | 76M | -24.7M | -1.6B | -1.5B | |
2.5B | 2.8B | 3B | 2.1B | 2B | 2B | 1.7B | 1.6B | 1.4B | |
INVESTING ACTIVITIES | |||||||||
-74.4M | -11M | -12.5M | -9.9M | -34.9M | -40.2M | -27M | -24.2M | -2M | |
-1.9B | -2.7B | -2.1B | -2.6B | -3.6B | -3.9B | -2.8B | -422.4M | -2.3B | |
566.5M | 118.4M | 25.8M | 1.5B | 1.8B | 1.2B | 875.1M | 750M | 600M | |
-175.1M | -49.3M | 29.4M | 0.0 | -18.1M | 15.1M | -250M | 0.0 | 115M | |
-1.6B | -2.7B | -2.1B | -1B | -1.9B | -2.8B | -2.2B | (303.4M) | -1.6B | |
FINANCING ACTIVITIES | |||||||||
-1.2B | -229.7M | -304.8M | 0.0 | 0.0 | 1.9B | -4.3M | 0.0 | 0.0 | |
954.5M | 1.5B | -1B | 0.0 | 1.3B | 680.6M | -294M | -294M | 907M | |
-378.3M | -376.5M | -358.3M | -333.3M | -285.2M | -397.8M | -739.3M | -814.4M | -735.2M | |
-1.2B | -229.7M | -304.8M | (0.0) | (0.0) | (0.0) | -4.3M | (0.0) | (0.0) | |
-534.8M | -504M | -485.7M | -611.5M | -602.2M | -704.4M | -154.1M | -270.7M | -295.1M | |
-1.2B | 361.1M | -2.1B | -944.9M | 385.1M | 1.5B | -1.2B | -1.4B | -123.3M | |
CASH FLOW SUMMARY | |||||||||
-310.3M | 452M | -1.2B | 169.7M | 532.4M | 762.5M | -1.7B | 542.6M | -292.6M | |
929M | 477M | 1.7B | 1.5B | 1B | 246.2M | 1.9B | 1.4B | 1.7B | |
618.7M | 929M | 477M | 1.7B | 1.5B | 1B | 246.2M | 1.9B | 1.4B | |
2.5B | 2.8B | 3B | 2.1B | 2B | 2B | 1.7B | 1.6B | 1.4B |
SEC Filings
RPRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 28, 2026 | May 22, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | June 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 11, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 22, 2025 | December 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 22, 2025 | December 20, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 |
Related Guides
Continue your RPRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.